CENTOGENE N.V., Am Strande 7, 18055 Rostock, Germany
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
United States
May 15, 2023
Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Ladies and Gentlemen,
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Centogene N.V. made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission on May 15, 2023. The disclosure can be found under the heading “Miscellaneous— Disclosure under Iran Threat Reduction and Syria Human Rights Act of 2012 (ITRA)” in the Annual Report on Form 20-F.
Respectfully submitted,
/s/ Kim Stratton | |
Kim Stratton | |
Chief Executive Officer | |
Centogene N.V. |
CENTOGENE N.V. | Management Board: | Statutory seat: |
Am Strande 7 | Kim Stratton (CEO) | Amsterdam, registered with the Kamer van |
18055 Rostock, Germany | Miguel Coego Rios (CFO) | Koophandel (Netherlands) under 72822872 |
Tel: +49 (0)381 80 113 - 400 | Prof. Peter Bauer M.D. (CMGO) | Bank account details: |
Fax: +49 (0)381 80 113 - 401 | Bank: Commerzbank AG | |
Email: info@centogene.com | Supervisory Board: | IBAN: DE60130400000108866500 |
www.centogene.com | Peer Schatz (Chairman) | BIC: COBADEFFXXX |